186 related articles for article (PubMed ID: 15058774)
1. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors.
Poirier VJ; Hershey AE; Burgess KE; Phillips B; Turek MM; Forrest LJ; Beaver L; Vail DM
J Vet Intern Med; 2004; 18(2):219-22. PubMed ID: 15058774
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia.
Poirier VJ; Burgess KE; Adams WM; Vail DM
J Vet Intern Med; 2004; 18(4):536-9. PubMed ID: 15320594
[TBL] [Abstract][Full Text] [Related]
3. Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case series.
Kim J; Doerr M; Kitchell BE
J Feline Med Surg; 2015 Feb; 17(2):186-90. PubMed ID: 24820996
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
[TBL] [Abstract][Full Text] [Related]
5. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia.
Selting KA; Bechtel SM; Espinosa J; Henry CJ; Tate D; Bryan JN; Rajewski L; Flesner BK; Decedue C; Baltezor M
Vet Comp Oncol; 2018 Dec; 16(4):650-657. PubMed ID: 30182530
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
8. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Choy H; Yee L; Cole BF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
[TBL] [Abstract][Full Text] [Related]
10. Multi-day fractionated administration schedule for paclitaxel.
Lokich J; Anderson N; Bern M; Coco F; Dow E; Moore C; Zipoli T; Gonzalves L
Ann Oncol; 1995 Nov; 6(9):883-5. PubMed ID: 8624290
[TBL] [Abstract][Full Text] [Related]
11. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Cartagena-Albertus JC; Engel Manchado J; Moise A; Moya García S; Montoya Alonso JA
Am J Vet Res; 2019 Jun; 80(6):601-606. PubMed ID: 31140850
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
18. The activity of paclitaxel in gastrointestinal tumors.
Ajani JA; Ilson DH; Kelsen DP
Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
